(DLB) Dolby Laboratories - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US25659T1079
DLB: Audio, Imaging, Codecs, Speakers, Amplifiers, Processors
Dolby Laboratories is a leader in audio and imaging technologies, shaping the entertainment experience across various platforms. From cinemas to home devices, Dolbys innovations enhance how we consume media. Their technologies like Dolby Atmos and Dolby Vision are staples in the industry, delivering immersive sound and visuals that redefine entertainment.
The companys portfolio includes a range of audio codecs such as AAC, HE-AAC, and Dolby AC-4, which are crucial for efficient media distribution. Dolby Atmos, their groundbreaking spatial audio technology, has become a standard in both cinemas and home theaters. On the visual side, Dolby Vision offers HDR capabilities that elevate image quality, making it a favorite among content creators and consumers alike.
eyond codecs, Dolby provides a suite of hardware and software solutions. Their digital cinema servers and processors are essential for modern theaters, ensuring high-quality audio and image reproduction. The company also caters to broader markets, including broadcast, gaming, and automotive industries, where their technologies enhance user experiences.
Financially, Dolby Laboratories presents an attractive profile for investors. With a market cap of over $8 billion, the company demonstrates stability and growth potential. The current P/E ratio of 31.29, coupled with a forward P/E of 19.42, suggests confidence in future earnings. A P/S ratio of 6.42 indicates strong revenue generation relative to its market value.
Investors should consider Dolbys consistent innovation and its role as a backbone of the entertainment industry. Their ability to adapt to emerging technologies and expand into new markets positions them as a resilient player in the tech sector. For fund managers, Dolbys financial health and industry leadership make it a compelling addition to a growth-oriented portfolio.
Additional Sources for DLB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DLB Stock Overview
Market Cap in USD | 7,861m |
Sector | Industrials |
Industry | Specialty Business Services |
GiC Sub-Industry | Electronic Components |
IPO / Inception | 2005-02-17 |
DLB Stock Ratings
Growth 5y | 7.44% |
Fundamental | 54.3% |
Dividend | 57.0% |
Rel. Strength Industry | -11.4 |
Analysts | 4.67/5 |
Fair Price Momentum | 69.10 USD |
Fair Price DCF | 42.04 USD |
DLB Dividends
Dividend Yield 12m | 1.58% |
Yield on Cost 5y | 1.91% |
Annual Growth 5y | 6.93% |
Payout Consistency | 85.7% |
DLB Growth Ratios
Growth Correlation 3m | 63.1% |
Growth Correlation 12m | -17.1% |
Growth Correlation 5y | 8.3% |
CAGR 5y | 4.28% |
CAGR/Max DD 5y | 0.11 |
Sharpe Ratio 12m | 0.11 |
Alpha | -15.44 |
Beta | 0.98 |
Volatility | 20.94% |
Current Volume | 646.1k |
Average Volume 20d | 507.8k |
As of February 23, 2025, the stock is trading at USD 81.57 with a total of 646,093 shares traded.
Over the past week, the price has changed by -2.60%, over one month by +0.50%, over three months by +2.46% and over the past year by +5.13%.
Partly, yes. Based on ValueRay Fundamental Analyses, Dolby Laboratories (NYSE:DLB) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 54.30 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DLB as of February 2025 is 69.10. This means that DLB is currently overvalued and has a potential downside of -15.29%.
Dolby Laboratories has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy DLB.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DLB Dolby Laboratories will be worth about 82.9 in February 2026. The stock is currently trading at 81.57. This means that the stock has a potential upside of +1.66%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 100 | 22.6% |
Analysts Target Price | 100 | 22.6% |
ValueRay Target Price | 82.9 | 1.7% |